AbbVie
4Q Revenues: $8.3 billion (+7%)
4Q Loss: $1.8 billion (earnings were $52,000 4Q17)
FY Revenues: $32.8 billion (+16%)
FY Earnings: $5.7 billion (+7%)
Comments: Global HUMIRA sales were $19.9 billion, up 8% for the year. In the U.S., HUMIRA sales grew 9% percent in the quarter. Internationally, HUMIRA sales declined 18% due to biosimilar competition.
Global revenues from the hematologic oncology portfolio were $1.1 billion for the year, up 50%, with global IMBRUVICA sales of $1.0 billion, an increase of 42%, and global VENCLEXTA revenues were $124 million. Fourth-quarter global HCV net revenues were $862 million.